Results 171 to 180 of about 573,436 (265)

Diffuse Large B-cell Lymphoma Presenting as a Hypermetabolic Mesenteric Root Mass Without Preoperative Imaging Suspicion of Lymphoma: A Case Report. [PDF]

Cureus
Li J, Jiang Q, Lu W.
europepmc   +1 more source

Analysis of interstitial lung disease in pharmacovigilance databases: Coding challenges and interpretation biases—An update

British Journal of Clinical Pharmacology, EarlyView.
Aim Clinically, interstitial lung disease (ILD) is a heterogeneous group of respiratory disorders. Due to their low incidence, pharmacovigilance database analysis is useful to detect them. Precise diagnosis is challenging as well as coding in these databases. Query criteria are among the key elements for a good signal detection.
Romane Freppel, Adeline Benis, Philippe Bonniaud, Jean‐Luc Faillie, Aurélie Grandvuillemin   +4 more
wiley   +1 more source

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

British Journal of Clinical Pharmacology, EarlyView.
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse, Christophe Hommel, Nadine Petitpain, Philippe Kerschen   +3 more
wiley   +1 more source

Harnessing the power of natural killer cells in Lymphoma immunotherapy: Overcoming challenges and enhancing treatment options. [PDF]

Hematol Transfus Cell Ther
Roshandel E, Lasemi MV, Mehravar M, Salimi M, Majidi M, Mohammadali F, Seraji HR, Hajifathali A.   +7 more
europepmc   +1 more source

Increasing the reporting of adverse drug reaction‐related hospitalizations using an ICD‐10‐based identification workflow: A multicentre study from Switzerland

British Journal of Clinical Pharmacology, EarlyView.
Background Reporting adverse drug reactions (ADRs) is essential for drug safety. In Switzerland, healthcare professionals are legally required to report serious and unlabelled ADRs, yet under‐reporting remains widespread. We tested a novel method to increase reporting of ADR‐related hospitalizations.
Georgia Anita Weber, Sophie‐Charlotte Bartel, Michael Boch, Christoph Rosen, Michael Bodmer, Balthasar Luzius Hug, Thomas Stammschulte, Patrick E. Beeler   +7 more
wiley   +1 more source

Evaluation of White Blood Cell Ratios in Newly Diagnosed Multicentric Lymphoma in Dogs. [PDF]

Vet Med Sci
Koenhemsi L, Güzelbakan SY, Tulobaev A, Yıldırım F.   +3 more
europepmc   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

BAL Flow Cytometry Unmasks Nodal T Follicular Helper Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis When Bone Marrow Is Nondiagnostic: A Case Report. [PDF]

Case Rep Pulmonol
Mwelwa MC.
europepmc   +1 more source

EBV & lymphoma

HemaSphere, 2019
openaire   +3 more sources